On December 11, 2019, the Board of Directors of Eidos Therapeutics, Inc. appointed Uma Sinha as a director of the Board, effective December 11, 2019. Uma Sinha, Ph.D., has served as the Company's Chief Scientific Officer since June 2016. Dr. Sinha has served as the chief scientific officer at BridgeBio Pharma, LLC since April 2016 and also currently serves as the chief scientific officer of other BridgeBio subsidiaries. Prior to that, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics, Inc. from 2014 to 2015 and as senior vice president of research from 2013 to 2014.